Titlebook: Chemotherapy for Leukemia; Novel Drugs and Trea Takanori Ueda Book 2017 Springer Nature Singapore Pte Ltd. 2017 Acute promyelocytic leukemi

只看該作者 · 發(fā)表于 2025-3-30 15:01:36

https://doi.org/10.1007/978-3-642-24440-7eatment strategy for B-CLL. The addition of anti-CD20 antibody to its management has remarkably improved the survival of B-CLL patients. Fludarabine, cyclophosphamide, and rituximab (FCR) is a standard treatment for physically fit patients without . defects, while bendamustine and rituximab (BR) is

只看該作者 · 發(fā)表于 2025-3-30 17:56:08

只看該作者 · 發(fā)表于 2025-3-30 21:50:08

		自動(dòng)登錄	找回密碼
密碼			To register

關(guān)于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務(wù)流程	影響因子官網(wǎng)	吾愛論文網(wǎng)	大講堂	北京大學(xué)	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點(diǎn)評	投稿經(jīng)驗(yàn)總結(jié)	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學(xué)	Yale Uni.	Stanford Uni.
\|Archiver\|手機(jī)版\|小黑屋\| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 10:43
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved